FDA staff reaffirm doubts about Replimune’s RP1 skin cancer application

FDA staff raise renewed questions about Replimune’s RP1 application

Regulators at the Food and Drug Administration have once again expressed reservations about the data supporting Replimune’s investigational skin cancer therapy, RP1, according to briefing documents released ahead of an advisory committee meeting later this week. The agency’s staff concluded that the evidence submitted does not adequately demonstrate the therapy’s efficacy or its systemic effects when delivered by local injection.

Replimune is seeking approval for RP1 for the third time. The FDA’s critique focuses largely on the clinical evidence the company submitted — in particular, a single-arm study in which patients who had previously been treated with PD-1 inhibitors received RP1 in combination with the PD-1 drug Opdivo. The agency said that study design is insufficient to determine how much of any observed benefit is attributable to RP1 itself.

What regulators objected to in the evidence

The FDA staff argued the single-arm trial cannot properly evaluate whether the locally injected therapy produces systemic benefits beyond the injected lesion. Because the study lacked a randomized control group receiving placebo or an alternative control, the agency said it is difficult to isolate RP1’s contribution to patient outcomes from the effects of prior or concurrent PD-1 therapy.

The briefing documents, released ahead of the advisory meeting, highlight the agency’s view that the current dataset does not meet the standards needed to support approval. The FDA’s commentary emphasizes concerns about trial design and the ability to draw firm conclusions regarding efficacy from the data Replimune provided.

Replimune’s response: feasibility and ethics of randomization

In its own briefing document to the same advisory committee, Replimune pushed back on the FDA staff’s objections. The company argued that conducting a randomized study that would assign patients to receive RP1 or a placebo in addition to PD-1 inhibitors would be “not feasible or ethical.” Replimune said there is no evidence that continued anti–PD-1 monotherapy benefits patients whose cancer has stopped responding to those agents, and that exposing such patients to a placebo on top of continued PD-1 therapy would be inappropriate.

That defense frames the dispute in ethical and practical terms: Replimune contends that the clinical situation of these patients makes the gold-standard randomized trial approach unrealistic, while the FDA staff maintain that the single-arm data do not allow a clear assessment of RP1’s effect.

The stakes: local injection, systemic claims, and regulatory standards

RP1 is administered by local injection into tumors, and a central regulatory question is whether such a local therapy can deliver meaningful systemic benefit. The FDA’s staff analysis specifically flagged uncertainty about whether observed improvements reflect a systemic therapeutic effect attributable to RP1, or whether they could be explained by other factors, including prior or concurrent PD-1 therapy.

This case highlights a recurring tension at the agency over what evidence is adequate for approval when randomized trials are difficult to conduct. The briefing documents make clear the FDA staff are applying a skeptical lens to single-arm results in this setting.

Advisory committee meeting and timeline

The FDA advisory committee was scheduled to review the Replimune application later in the week after the July 28, 2026 briefing documents were released. The STAT article reporting these staff concerns appeared on July 28, 2026. The source indicates the committee meeting will take place shortly after the briefing materials were posted, but it does not include the committee’s vote or the agency’s final decision.

What the STAT report does and does not provide

The STAT story summarizes the central disagreement between FDA staff and Replimune: agency reviewers criticize the reliance on a single-arm combination trial to support approval of RP1, while the company argues that a randomized trial would be infeasible and unethical for the target patient population. Specific trial results, detailed numerical outcomes, patient numbers, endpoints, and the full content of the briefing documents were not included in the portion of the article available in the source. The report also does not provide the advisory committee’s recommendation or any subsequent FDA action.

Context within broader regulatory debates

The exchange between FDA staff and Replimune fits into ongoing debates about acceptable evidence standards when evaluating innovative cancer therapies, particularly when trials are nonrandomized or rely on historical comparisons. The case underscores the difficulty regulators and sponsors face when balancing methodological rigor against clinical feasibility and ethical considerations in patients who have exhausted standard therapies.

What’s next

The immediate next step described in the source is the advisory committee meeting later in the week, where the FDA advisers will review the application and the competing arguments from agency staff and the sponsor. The STAT article does not report the outcome of that meeting or any subsequent regulatory decision. Further details about the trial data, the advisers’ discussion, and any agency action were not provided in the source material.

If readers want the final outcome of the advisory panel or the FDA’s decision, those results were not contained in the STAT excerpt provided and would need to be obtained from follow-up coverage, the full briefing documents, or the FDA’s public docket.